Investment Thesis
Intensity Therapeutics is a pre-commercial stage biotech company with an exceptionally strong balance sheet (83% of assets in cash, zero debt) and improving losses, but lacks any revenue generation and continues to burn cash. The solid financial foundation provides runway (~5.7 years at current burn rate), yet future viability depends entirely on clinical/product pipeline success, which cannot be assessed from financial data alone.
Strengths
- Fortress balance sheet with $10.2M cash against $2.3M liabilities and zero debt
- Excellent liquidity position (4.86x current and quick ratios)
- Improving loss trajectory year-over-year (net income loss decreased 28.7%, EPS improved 70.7%), indicating operational discipline
Risks
- Complete lack of revenue; pre-commercial development stage with uncertain commercialization timeline
- Ongoing operating and free cash flow burn (-$1.8M annually) with no path to profitability visible
- Minimal insider activity (1 Form 4 filing in 90 days) suggests limited insider confidence or engagement
- High execution risk inherent to biotech sector; clinical trial failures could rapidly deplete cash runway
Key Metrics to Watch
- Cash burn rate trends and runway extension/contraction
- Clinical trial progress and FDA regulatory milestones
- Gross margin upon revenue generation and path to positive operating cash flow
Financial Metrics
Revenue
N/A
Net Income
-2.4M
EPS (Diluted)
$-0.96
Free Cash Flow
-1.8M
Total Assets
12.3M
Cash
10.2M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-24.4%
ROA
-19.8%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
4.86x
Quick Ratio
4.86x
Debt/Equity
0.00x
Debt/Assets
18.8%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-14T08:37:03.341436 |
Data as of: 2026-03-31 |
Powered by Claude AI